Search

Your search keyword '"Kitchlu A"' showing total 18 results
Start Over Author "Kitchlu A" Publication Type Electronic Resources
18 results on '"Kitchlu A"'

1. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI.

Author

Gupta, Shruti, Gupta, Shruti, Garcia-Carro, Clara, Prosek, Jason, Glezerman, Ilya, Herrmann, Sandra, Garcia, Pablo, Abudayyeh, Ala, Lumlertgul, Nuttha, Malik, A, Loew, Sebastian, Beckerman, Pazit, Renaghan, Amanda, Carlos, Christopher, Rashidi, Arash, Mithani, Zain, Deshpande, Priya, Rangarajan, Sunil, Shah, Chintan, Seigneux, Sophie, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel, Coppock, Gaia, Ortiz-Melo, David, Sprangers, Ben, Aggarwal, Vikram, Benesova, Karolina, Wanchoo, Rimda, Murakami, Naoka, Cortazar, Frank, Reynolds, Kerry, Sise, Meghan, Soler, Maria, Leaf, David, Gupta, Shruti, Gupta, Shruti, Garcia-Carro, Clara, Prosek, Jason, Glezerman, Ilya, Herrmann, Sandra, Garcia, Pablo, Abudayyeh, Ala, Lumlertgul, Nuttha, Malik, A, Loew, Sebastian, Beckerman, Pazit, Renaghan, Amanda, Carlos, Christopher, Rashidi, Arash, Mithani, Zain, Deshpande, Priya, Rangarajan, Sunil, Shah, Chintan, Seigneux, Sophie, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel, Coppock, Gaia, Ortiz-Melo, David, Sprangers, Ben, Aggarwal, Vikram, Benesova, Karolina, Wanchoo, Rimda, Murakami, Naoka, Cortazar, Frank, Reynolds, Kerry, Sise, Meghan, Soler, Maria, and Leaf, David

Abstract

BACKGROUND: Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free survival among patients treated with ICPis. We sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared with a longer duration. METHODS: We used data from an international multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across nine countries. We examined whether a shorter duration of corticosteroids (28 days or less) was associated with a higher rate of recurrent ICPi-AKI or death within 30 days following completion of corticosteroid treatment as compared with a longer duration (29-84 days). RESULTS: Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in the shorter versus longer duration groups were similar with respect to baseline and ICPi-AKI characteristics. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (p=0.90). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar between groups (p=0.40, p=0.56, and p=0.89, respectively). CONCLUSION: A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.

Published
2022

2. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Author

Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, Liu, Geoffrey, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, and Liu, Geoffrey

Published
2021

3. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Author

Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, Liu, Geoffrey, Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, and Liu, Geoffrey

Published
2021

4. Acute kidney injury in patients treated with immune checkpoint inhibitors.

Author

Gupta, Shruti, Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, Seigneux, Sophie De, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Sarvode Mothi, Suraj, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, ICPi-AKI Consortium Investigators, Gupta, Shruti, Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, Seigneux, Sophie De, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Sarvode Mothi, Suraj, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, and ICPi-AKI Consortium Investigators

Abstract

Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. ICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

Published
2021

5. Acute kidney injury in patients treated with immune checkpoint inhibitors.

Author

Gupta, Shruti, Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, Seigneux, Sophie De, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Sarvode Mothi, Suraj, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, ICPi-AKI Consortium Investigators, Gupta, Shruti, Gupta, Shruti, Short, Samuel AP, Sise, Meghan E, Prosek, Jason M, Madhavan, Sethu M, Soler, Maria Jose, Ostermann, Marlies, Herrmann, Sandra M, Abudayyeh, Ala, Anand, Shuchi, Glezerman, Ilya, Motwani, Shveta S, Murakami, Naoka, Wanchoo, Rimda, Ortiz-Melo, David I, Rashidi, Arash, Sprangers, Ben, Aggarwal, Vikram, Malik, A Bilal, Loew, Sebastian, Carlos, Christopher A, Chang, Wei-Ting, Beckerman, Pazit, Mithani, Zain, Shah, Chintan V, Renaghan, Amanda D, Seigneux, Sophie De, Campedel, Luca, Kitchlu, Abhijat, Shin, Daniel Sanghoon, Rangarajan, Sunil, Deshpande, Priya, Coppock, Gaia, Eijgelsheim, Mark, Seethapathy, Harish, Lee, Meghan D, Strohbehn, Ian A, Owen, Dwight H, Husain, Marium, Garcia-Carro, Clara, Bermejo, Sheila, Lumlertgul, Nuttha, Seylanova, Nina, Flanders, Lucy, Isik, Busra, Mamlouk, Omar, Lin, Jamie S, Garcia, Pablo, Kaghazchi, Aydin, Khanin, Yuriy, Kansal, Sheru K, Wauters, Els, Chandra, Sunandana, Schmidt-Ott, Kai M, Hsu, Raymond K, Tio, Maria C, Sarvode Mothi, Suraj, Singh, Harkarandeep, Schrag, Deborah, Jhaveri, Kenar D, Reynolds, Kerry L, Cortazar, Frank B, Leaf, David E, and ICPi-AKI Consortium Investigators

Abstract

Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. ICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.

Published
2021

6. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Author

Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, Liu, Geoffrey, Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, and Liu, Geoffrey

Published
2021

7. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.

Author

Murakami, Naoka, Murakami, Naoka, Mulvaney, Patrick, Danesh, Melissa, Abudayyeh, Ala, Diab, Adi, Abdel-Wahab, Noha, Abdelrahim, Maen, Khairallah, Pascale, Shirazian, Shayan, Kukla, Aleksandra, Owoyemi, Itunu O, Alhamad, Tarek, Husami, Samir, Menon, Madhav, Santeusanio, Andrew, Blosser, Christopher D, Zuniga, Sandra Carias, Soler, Maria Jose, Moreso, Francesc, Mithani, Zain, Ortiz-Melo, David, Jaimes, Edgar A, Gutgarts, Victoria, Lum, Erik, Danovitch, Gabriel M, Cardarelli, Francesca, Drews, Reed E, Bassil, Claude, Swank, Jennifer L, Westphal, Scott, Mannon, Roslyn B, Shirai, Keisuke, Kitchlu, Abhijat, Ong, Song, Machado, Shana M, Mothi, Suraj S, Ott, Patrick A, Rahma, Osama, Hodi, F Stephen, Sise, Meghan E, Gupta, Shruti, Leaf, David E, Devoe, Craig E, Wanchoo, Rimda, Nair, Vinay V, Schmults, Chrysalyne D, Hanna, Glenn J, Sprangers, Ben, Riella, Leonardo V, Jhaveri, Kenar D, Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium, Murakami, Naoka, Murakami, Naoka, Mulvaney, Patrick, Danesh, Melissa, Abudayyeh, Ala, Diab, Adi, Abdel-Wahab, Noha, Abdelrahim, Maen, Khairallah, Pascale, Shirazian, Shayan, Kukla, Aleksandra, Owoyemi, Itunu O, Alhamad, Tarek, Husami, Samir, Menon, Madhav, Santeusanio, Andrew, Blosser, Christopher D, Zuniga, Sandra Carias, Soler, Maria Jose, Moreso, Francesc, Mithani, Zain, Ortiz-Melo, David, Jaimes, Edgar A, Gutgarts, Victoria, Lum, Erik, Danovitch, Gabriel M, Cardarelli, Francesca, Drews, Reed E, Bassil, Claude, Swank, Jennifer L, Westphal, Scott, Mannon, Roslyn B, Shirai, Keisuke, Kitchlu, Abhijat, Ong, Song, Machado, Shana M, Mothi, Suraj S, Ott, Patrick A, Rahma, Osama, Hodi, F Stephen, Sise, Meghan E, Gupta, Shruti, Leaf, David E, Devoe, Craig E, Wanchoo, Rimda, Nair, Vinay V, Schmults, Chrysalyne D, Hanna, Glenn J, Sprangers, Ben, Riella, Leonardo V, Jhaveri, Kenar D, and Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium

Abstract

Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However, their safety and efficacy in patients with a kidney transplant have not been defined. To delineate this, we conducted a multicenter retrospective study of 69 patients with a kidney transplant receiving ICIs between January 2010 and May 2020. For safety, we assessed the incidence, timing, and risk factors of acute graft rejection. For efficacy, objective response rate and overall survival were assessed in cutaneous squamous cell carcinoma and melanoma, the most common cancers in our cohort, and compared with stage-matched 23 patients with squamous cell carcinoma and 14 with melanoma with a kidney transplant not receiving ICIs. Following ICI treatment, 29 out of 69 (42%) patients developed acute rejection, 19 of whom lost their allograft, compared with an acute rejection rate of 5.4% in the non-ICI cohort. Median time from ICI initiation to rejection was 24 days. Factors associated with a lower risk of rejection were mTOR inhibitor use (odds ratio 0.26; 95% confidence interval, 0.09-0.72) and triple-agent immunosuppression (0.67, 0.48-0.92). The objective response ratio was 36.4% and 40% in the squamous cell carcinoma and melanoma subgroups, respectively. In the squamous cell carcinoma subgroup, overall survival was significantly longer in patients treated with ICIs (median overall survival 19.8 months vs. 10.6 months), whereas in the melanoma subgroup, overall survival did not differ between groups. Thus, ICIs were associated with a high risk of rejection in patients with kidney transplants but may lead to improved cancer outcomes. Prospective studies are needed to determine optimal immunosuppression strategies to improve patient outcomes.

Published
2021

8. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Author

Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, Liu, Geoffrey, Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Zazuli, Zulfan, Jong, Corine de de, Xu, Wei, Vijverberg, Susanne J. H., Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shao Hui, Spreafico, Anna, Hansen, Aaron R., Goldstein, David P., Almeida, John R. de de, Bratman, Scott V., Hope, Andrew, Knox, Jennifer J., Wong, Rebecca K. S., Darling, Gail E., Kitchlu, Abhijat, Haarlem, Simone W. A. van van, Meer, Femke van der, Lindert, Anne S. R. van, Heuvel, Alexandra ten ten, Brouwer, Jan, Ross, Colin J. D., Carleton, Bruce C., Egberts, Toine C. G., Herder, Gerarda J. M., Deneer, Vera H. M., Zee, Anke H. Maitland-van der, and Liu, Geoffrey

Published
2021

9. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study

Author

Apotheek Onderzoek, Apotheek Opleiding, Cancer, Arts Assistenten Longziekten, Longziekten, Infection & Immunity, Brain, Child Health, Regenerative Medicine and Stem Cells, Apotheek Klinische Farmacie, Zazuli, Zulfan, de Jong, Corine, Xu, Wei, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shaohui, Spreafico, Anna, Hansen, Aaron R, Goldstein, David P, de Almeida, John R, Bratman, Scott V, Hope, Andrew, Knox, Jennifer J, Wong, Rebecca K S, Darling, Gail E, Kitchlu, Abhijat, van Haarlem, Simone W A, van der Meer, Femke, van Lindert, Anne S R, Ten Heuvel, Alexandra, Brouwer, Jan, Ross, Colin J D, Carleton, Bruce C, Egberts, Toine C G, Herder, Gerarda J M, Deneer, Vera H M, Maitland-van der Zee, Anke H, Liu, Geoffrey, Apotheek Onderzoek, Apotheek Opleiding, Cancer, Arts Assistenten Longziekten, Longziekten, Infection & Immunity, Brain, Child Health, Regenerative Medicine and Stem Cells, Apotheek Klinische Farmacie, Zazuli, Zulfan, de Jong, Corine, Xu, Wei, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Patel, Devalben, Mirshams, Maryam, Khan, Khaleeq, Cheng, Dangxiao, Ordonez-Perez, Bayardo, Huang, Shaohui, Spreafico, Anna, Hansen, Aaron R, Goldstein, David P, de Almeida, John R, Bratman, Scott V, Hope, Andrew, Knox, Jennifer J, Wong, Rebecca K S, Darling, Gail E, Kitchlu, Abhijat, van Haarlem, Simone W A, van der Meer, Femke, van Lindert, Anne S R, Ten Heuvel, Alexandra, Brouwer, Jan, Ross, Colin J D, Carleton, Bruce C, Egberts, Toine C G, Herder, Gerarda J M, Deneer, Vera H M, Maitland-van der Zee, Anke H, and Liu, Geoffrey

Published
2021

10. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation

Author

Małyszko, J. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Porta, C. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. Tesař, V. Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E. Conference Participants and Małyszko, J. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Porta, C. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. Tesař, V. Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E. Conference Participants

Abstract

The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed. © 2020 Kidney Disease: Improving Global Outcomes (KDIGO)

Published
2020

11. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Author

Porta, C. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Małyszko, J. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. ladimír Tesař Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E. and Porta, C. Bamias, A. Danesh, F.R. Dębska-Ślizień, A. Gallieni, M. Gertz, M.A. Kielstein, J.T. Tesarova, P. Wong, G. Cheung, M. Wheeler, D.C. Winkelmayer, W.C. Małyszko, J. Abu-Alfa, A.K. Amer, H. Beutel, G. Chapman, J. Chen, X. Chudek, J. Cosmai, L. Danesi, R. De Stefano, F. Iseki, K. Jaimes, E.A. Jhaveri, K.D. Jurczyszyn, A. Kazancioğlu, R. Kitchlu, A. Kollmannsberger, C. Lahoti, A. Li, Y. Macía, M. Matsubara, T. Mitropoulos, D. Noiri, E. Perazella, M.A. Ronco, P. Rosner, M.H. Soler Romeo, M.J. Sprangers, B. Stadler, W.M. Stevens, P.E. ladimír Tesař Torres da Costa e Silva, V. Vesole, D.H. Vijayan, A. Viklický, O. Workeneh, B.T. Yanagita, M. Zakharova, E.

Abstract

The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues in the setting of malignancy can worsen patient outcomes and diminish the adequacy of anticancer treatments. In addition, the oncology treatment landscape is changing rapidly, and data on tolerability of novel therapies in patients with CKD are often lacking. Caring for oncology patients has become more specialized and interdisciplinary, currently requiring collaboration among specialists in nephrology, medical oncology, critical care, clinical pharmacology/pharmacy, and palliative care, in addition to surgeons and urologists. To identify key management issues in nephrology relevant to patients with malignancy, KDIGO (Kidney Disease: Improving Global Outcomes) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology in December 2018. This report covers issues related to kidney impairment and solid organ malignancies as well as management and treatment of kidney cancer. Knowledge gaps, areas of controversy, and research priorities are described. © 2020 Kidney Disease:Improving Global Outcomes (KDIGO)

Published
2020

12. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

Author

Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, Maitland-van der Zee, Anke H, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, and Maitland-van der Zee, Anke H

Abstract

Although previous research identified candidate genetic polymorphisms associated with cisplatin nephrotoxicity, varying outcome definitions potentially contributed to the variability in the effect size and direction of this relationship. We selected genetic variants that have been significantly associated with cisplatin-induced nephrotoxicity in more than one published study (SLC22A2 rs316019; ERCC1 rs11615 and rs3212986; ERCC2 rs1799793 and rs13181) and performed a replication analysis to confirm associations between these genetic polymorphisms and cisplatin nephrotoxicity using various outcome definitions. We included 282 germ cell testicular cancer patients treated with cisplatin from 2009-2014, aged >17 years recruited by the Canadian Pharmacogenomics Network for Drug Safety. Nephrotoxicity was defined using four grading tools: (1) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for acute kidney injury (AKI) or CTCAE-AKI; (2) adjusted cisplatin-induced AKI; (3) elevation of serum creatinine; and (4) reduction in the estimated glomerular filtration rate (eGFR). Significant associations were only found when using the CTCAE v4.03 definition: genotype CA of the ERCC1 rs3212986 was associated with decreased risk of cisplatin nephrotoxicity (ORadj = 0.24; 95% CI:0.08-0.70; p= 0.009) compared to genotype CC. In contrast, addition of allele A at SLC22A2 rs316019 was associated with increased risk (ORadj = 4.41; 95% CI:1.96-9.88; p < 0.001) while genotype AC was associated with a higher risk of cisplatin nephrotoxicity (ORadj = 5.06; 95% CI:1.69-15.16; p= 0.004) compared to genotype CC. Our study showed that different case definitions led to variability in the genetic risk ascertainment of cisplatin nephrotoxicity. Therefore, consensus on a set of clinically relevant outcome definitions that all such studies should follow is needed.

Published
2019

13. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

Author

Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, Maitland-van der Zee, Anke H, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, and Maitland-van der Zee, Anke H

Published
2019

14. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

Author

Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, Maitland-van der Zee, Anke H, Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, and Maitland-van der Zee, Anke H

Published
2019

15. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

Author

Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, Maitland-van der Zee, Anke H, Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, and Maitland-van der Zee, Anke H

Published
2019

16. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients

Author

Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, Maitland-van der Zee, Anke H, Afd Pharmacology, Pharmacology, Zazuli, Zulfan, Otten, Leila S, Drögemöller, Britt I, Medeiros, Mara, Monzon, Jose G, Wright, Galen E B, Kollmannsberger, Christian K, Bedard, Philippe L, Chen, Zhuo, Gelmon, Karen A, McGoldrick, Nicole, Kitchlu, Abhijat, Vijverberg, Susanne J H, Masereeuw, Rosalinde, Ross, Colin J D, Liu, Geoffrey, Carleton, Bruce C, and Maitland-van der Zee, Anke H

Published
2019

17. Forman Christian College Magazine. V.24 No.04. Apr. 1933

Author

Lucas, E. D.; Benade, J. M.; Dhamija, J. N.; Indra Narain Bhatnagar; Mathai, S.; Kitchlu, S.; Aziz-ur-Rahman; Yogendra Nath; Anwar, M. M., Velte, F. M.; Ata Ullah Khan, Kalim, Lucas, E. D.; Benade, J. M.; Dhamija, J. N.; Indra Narain Bhatnagar; Mathai, S.; Kitchlu, S.; Aziz-ur-Rahman; Yogendra Nath; Anwar, M. M., and Velte, F. M.; Ata Ullah Khan, Kalim

Abstract

Valedictory number 1933, Lucas, E. D.-Valedictory lecture-Life and Education. pp. 1-7; Benade, J. M.-Travelogues-The Cosmic Ray Expedition to S. E. Ladakh. pp. 8-16; Dhamija, J. N.-Essay-Poetry and the Modern Age: science condemned. pp. 17-21; Essay-Poetry in an age of Science. pp. 21-26; Essay-My Diary. pp. 26-28; Indra Narain Bhatnagar-Essay-Our Modern Age. pp. 28-31; Mathai, S.-Essay-Illusion. pp. 31-34; Kitchlu, S.-Essay-Co-Education. pp. 34-36; Aziz-ur-Rahman-Essay-The Flower of Ujjain. pp. 36-37; Mathai, S.-Essay-Criticism as a Form of Literature. pp. 38-43; Yogendra Nath-Essay-Splitting the Atom: a fantasy. pp. 43-46; Anwar, M. M.-Essay-John Masefield's Dramatic Work. pp. 46-54; News and Notes. pp. 55-57; New books in Library. pp. 58-59; The Examinee's. pp. 60; Music. pp. 60, Rev. E. D. Lucas, D. D. Ph. D., after the title page; Chaudhri Munir Ahmad, Captain, University Athletics Team, 1932-33. after page 60

Published
1933

18. Forman Christian College Magazine. V.23 No.06-07. March-April. 1932

Author

Jain, M. P.; Darling, M. L.; Bhatty, M. S.; Kitchlu, S.; Aziz-ur-Rahman; Mohd. Yamin Qureshi; Ram Dhan Kwatra; Hardyal Singh; Krishan Chander; Maqbool Elahi; Patrick, B. N.; Malik, A. Rashid; Jagdish Singh, Dean, E. T.; Velte, F. M.; Ata Ullah Kalim; Maqbool Elahi; Aziz-ur-Rahman; Ismail, M. M. [Urdu]; Mehr Lal Soni, Zia [Urdu]; Dev Raj [Hindi]; Jagdish Singh [Punjabi], Jain, M. P.; Darling, M. L.; Bhatty, M. S.; Kitchlu, S.; Aziz-ur-Rahman; Mohd. Yamin Qureshi; Ram Dhan Kwatra; Hardyal Singh; Krishan Chander; Maqbool Elahi; Patrick, B. N.; Malik, A. Rashid; Jagdish Singh, and Dean, E. T.; Velte, F. M.; Ata Ullah Kalim; Maqbool Elahi; Aziz-ur-Rahman; Ismail, M. M. [Urdu]; Mehr Lal Soni, Zia [Urdu]; Dev Raj [Hindi]; Jagdish Singh [Punjabi]

Abstract

Jain, M. P.-Editorial. pp. 1-2; Darling, M. L.-Speech-Live Hard and Live Well. pp. 3-7; Bhatty, M. S.-Article-Disarmament II. pp. 8-14; The Skull of a Young Woman. pp. 14-15; Kitchlu, S.-Essay-National Education in India. pp. 15-16; Aziz-ur-Rahman-Essay-In Defence of Cramming. pp. 16-18; Mohd. Yamin Qureshi-A Cup of Tea. pp. 18-20; Ram Dhan Kwatra-Away From the World. pp. 20-21; Hardyal Singh-Beauty. pp. 21-22; Krishan Chander-You and I. pp. 22-23; Maqbool Elahi-My Friend. pp. 24-25; Patrick, B. N.-Poetry-Love Me for Ever. pp. 25; Poetry-Cupid's Stock Taking. pp. 25-26; Maqbool Elahi-Of Lesser Order. pp. 26-27; Malik, A. Rashid-Initiation. pp. 27-28; Aziz-ur-Rahman-News and Notes. pp. 29-33; Jagdish Singh-Hostel News. pp. 33-36; [Hindi]. 6 p.; Punjabi Kiyari [Punjabi] pp. 21-32; Khisa-e-Urdu [Urdu]. 20 p.

Published
1932

Catalog

Books, media, physical & digital resources
See catalog results